The novel benzimidazole derivativeBRP‐7 inhibits leukotriene biosynthesisin vitroandin vivoby targeting 5‐lipoxygenase‐activating protein (FLAP)

Authors:

Abstract
Background and Purpose: Leukotrienes (LTs) are inflammatory mediators produced via the 5‐lipoxygenase (5‐LOX) pathway and are linked to diverse disorders, including asthma, allergic rhinitis and cardiovascular diseases. We recently identified the benzimidazole derivativeBRP‐7 as chemotype for anti‐LTagents by virtual screening targeting 5‐LOX‐activating protein (FLAP). Here, we aimed to reveal thein vitroandin vivopharmacology ofBRP‐7 as an inhibitor ofLTbiosynthesis.Experimental Approach: We analysedLTformation and performed mechanistic studies in human neutrophils and monocytes, in human whole blood (HWB) and in cell‐free assays. The effectiveness ofBRP‐7in vivowas evaluated in rat carrageenan‐induced pleurisy and mouse zymosan‐induced peritonitis.Key Results: BRP‐7 potently suppressedLTformation in neutrophils and monocytes and this was accompanied by impaired 5‐LOXco‐localization withFLAP. Neither the cellular viability nor the activity of 5‐LOXin cell‐free assays was affected byBRP‐7, indicating that a functionalFLAPis needed forBRP‐7 to inhibit LTs, andFLAPbound toBRP‐7 linked to a solid matrix. Compared with theFLAPinhibitorMK‐886,BRP‐7 did not significantly inhibitCOX‐1 or microsomal prostaglandinE2synthase‐1, implying the selectivity ofBRP‐7 forFLAP. Finally,BRP‐7 was effective inHWBand impaired inflammationin vivo, in rat pleurisy and mouse peritonitis, along with reducingLTlevels.Conclusions and Implications: BRP‐7 potently suppressesLTbiosynthesis by interacting withFLAPand exhibits anti‐inflammatory effectivenessin vivo, with promising potential for further development.

This publication has 48 references indexed in Scilit: